West Pharmaceutical Services, Inc.
WST
$263.51
-$15.59-5.59%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.96B | 2.90B | 2.89B | 2.88B | 2.88B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.96B | 2.90B | 2.89B | 2.88B | 2.88B |
| Cost of Revenue | 1.92B | 1.90B | 1.89B | 1.87B | 1.85B |
| Gross Profit | 1.04B | 1.00B | 998.50M | 1.00B | 1.03B |
| SG&A Expenses | 346.30M | 334.80M | 334.90M | 342.30M | 349.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 1.20M | 900.00K | 900.00K | 1.90M | 900.00K |
| Total Operating Expenses | 2.33B | 2.30B | 2.30B | 2.29B | 2.27B |
| Operating Income | 627.20M | 596.70M | 593.60M | 589.80M | 606.40M |
| Income Before Tax | 611.20M | 582.40M | 600.20M | 604.80M | 627.10M |
| Income Tax Expenses | 123.50M | 115.20M | 107.50M | 105.20M | 102.20M |
| Earnings from Continuing Operations | 487.70 | 467.20 | 492.70 | 499.60 | 524.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 487.70M | 467.20M | 492.70M | 499.60M | 524.90M |
| EBIT | 627.20M | 596.70M | 593.60M | 589.80M | 606.40M |
| EBITDA | 789.50M | 756.50M | 749.00M | 740.40M | 752.50M |
| EPS Basic | 6.72 | 6.42 | 6.75 | 6.81 | 7.11 |
| Normalized Basic EPS | 5.58 | 5.29 | 5.27 | 5.20 | 5.35 |
| EPS Diluted | 6.68 | 6.37 | 6.69 | 6.73 | 7.02 |
| Normalized Diluted EPS | 5.54 | 5.25 | 5.22 | 5.15 | 5.29 |
| Average Basic Shares Outstanding | 290.20M | 291.00M | 292.00M | 293.40M | 294.90M |
| Average Diluted Shares Outstanding | 292.20M | 293.40M | 294.70M | 296.40M | 298.30M |
| Dividend Per Share | 0.83 | 0.82 | 0.81 | 0.80 | 0.79 |
| Payout Ratio | 12.32% | 12.76% | 12.00% | 11.73% | 11.07% |